314 related articles for article (PubMed ID: 27506946)
1. A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
Gallou C; Rougeot A; Graff-Dubois S; Kosmatopoulos K; Menez-Jamet J
Oncotarget; 2016 Sep; 7(37):59417-59428. PubMed ID: 27506946
[TBL] [Abstract][Full Text] [Related]
2. Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo.
Horiuchi Y; Takagi A; Uchida T; Akatsuka T
Oncol Rep; 2015 Dec; 34(6):2827-36. PubMed ID: 26398429
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
4. Development of optimized cryptic peptides for immunotherapy.
Menez-Jamet J; Kosmatopoulos K
IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
[TBL] [Abstract][Full Text] [Related]
5. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
Lu J; Celis E
Cancer Res; 2000 Sep; 60(18):5223-7. PubMed ID: 11016651
[TBL] [Abstract][Full Text] [Related]
6. Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines.
Menez-Jamet J; Gallou C; Rougeot A; Kosmatopoulos K
Ann Transl Med; 2016 Jul; 4(14):266. PubMed ID: 27563653
[TBL] [Abstract][Full Text] [Related]
7. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
[TBL] [Abstract][Full Text] [Related]
8. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy.
Scardino A; Gross DA; Alves P; Schultze JL; Graff-Dubois S; Faure O; Tourdot S; Chouaib S; Nadler LM; Lemonnier FA; Vonderheide RH; Cardoso AA; Kosmatopoulos K
J Immunol; 2002 Jun; 168(11):5900-6. PubMed ID: 12023395
[TBL] [Abstract][Full Text] [Related]
9. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes.
Tourdot S; Scardino A; Saloustrou E; Gross DA; Pascolo S; Cordopatis P; Lemonnier FA; Kosmatopoulos K
Eur J Immunol; 2000 Dec; 30(12):3411-21. PubMed ID: 11093159
[TBL] [Abstract][Full Text] [Related]
10. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
[TBL] [Abstract][Full Text] [Related]
11. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).
Koumantou D; Barnea E; Martin-Esteban A; Maben Z; Papakyriakou A; Mpakali A; Kokkala P; Pratsinis H; Georgiadis D; Stern LJ; Admon A; Stratikos E
Cancer Immunol Immunother; 2019 Aug; 68(8):1245-1261. PubMed ID: 31222486
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M
Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
[TBL] [Abstract][Full Text] [Related]
14. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.
Tine JA; Firat H; Payne A; Russo G; Davis SW; Tartaglia J; Lemonnier FA; Demoyen PL; Moingeon P
Vaccine; 2005 Jan; 23(8):1085-91. PubMed ID: 15620483
[TBL] [Abstract][Full Text] [Related]
15. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.
Han JF; Zhao TT; Liu HL; Lin ZH; Wang HM; Ruan ZH; Zou LY; Wu YZ
Cancer Immunol Immunother; 2006 Dec; 55(12):1575-83. PubMed ID: 16534571
[TBL] [Abstract][Full Text] [Related]
16. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
17. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
18. The immunogenicity of a novel cytotoxic T lymphocyte epitope from tumor antigen PL2L60 could be enhanced by 4-chlorophenylalanine substitution at position 1.
Shi RR; Liu J; Zou Z; Qi YM; Zhai MX; Zhai WJ; Gao YF
Cancer Immunol Immunother; 2013 Nov; 62(11):1723-32. PubMed ID: 24077852
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
20. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
Gross DA; Graff-Dubois S; Opolon P; Cornet S; Alves P; Bennaceur-Griscelli A; Faure O; Guillaume P; Firat H; Chouaib S; Lemonnier FA; Davoust J; Miconnet I; Vonderheide RH; Kosmatopoulos K
J Clin Invest; 2004 Feb; 113(3):425-33. PubMed ID: 14755339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]